Only 10% of drugs entering clinical development for autoimmune or inflammatory diseases are eventually approved, mainly due to a lack of efficacy and our poor understanding of disease mechanisms.
Genetics plays a crucial role in improving therapies for autoimmune diseases, with hundreds of loci linked to disease pathogenesis. Drugs targeting pathways supported by genetics have higher chances of effectiveness.
Identifying how non-coding genetic variants drive diseases is challenging, as the same DNA sequences function differently based on cell types and external factors. This difficulty hampers efforts to pinpoint disease mechanisms.
[
add
]
[
|
|
...
]